Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00165178 · ClinicalTrials.gov registry record · Phase 3
Treatment of Acute Lymphoblastic Leukemia in Children
A Phase 3 study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- Phase 3
- Development phase
- 498
- Enrollment target
NCT00165178: Completed Phase 3 study, sponsored by Dana-Farber Cancer Institute.
NCT00165178 is a Phase 3 study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 498 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (35% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00165178, a Phase 3 study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 498 participants
- Enrollment target
Study Summary
The purpose of this study is to reduce the side-effects from anti-leukemia therapy. The therapy in this study is based upon treatment information learned from prior clinical research programs as well as from laboratory research.
Interventions
- DRUG prednisone
- DRUG dexamethasone
- DRUG doxorubicin
- DRUG vincristine
- DRUG E. coli asparaginase
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 498 participants |
| Start Date | 2000-09 |
| Est. Completion | 2011-05 |
| Phase | Phase 3 |
What the finished NCT00165178 record still lists
NCT00165178 is an interventional study that assigns participants to a tested intervention. The registered 498 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (35% lower).
The record links to 0 conditions, and to 5 interventions - of which prednisone is the first listed.
NCT00165178 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00165178 about?
NCT00165178 is a clinical study titled "Treatment of Acute Lymphoblastic Leukemia in Children". The purpose of this study is to reduce the side-effects from anti-leukemia therapy. The therapy in this study is based upon treatment information learned from prior clinical research programs as well as from laboratory research.
What is the current status of trial NCT00165178?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 498 participants. The study started on 2000-09. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00165178?
The interventions under investigation include: prednisone (DRUG), dexamethasone (DRUG), doxorubicin (DRUG), vincristine (DRUG), E. coli asparaginase (DRUG).
Who is sponsoring clinical trial NCT00165178?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00165178's enrollment target sits among peer trials
498 775th of 2000 higher than 1,226 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04137900 · 499 participants · Phase 1
Safety, Tolerability and Pharmacokinetics of a Monoclonal Antibody Specific to B-and T-Lymphocyte Attenuator (BTLA) as Monotherapy and in Combination With an Anti-PD1 Monoclonal Antibody for Injection in Subjects With Advanced Malignancies
- NCT06733480 · 499 participants · NA
Innovating Physical Therapy: A Pilot Study on Band Connect's Impact on Compliance, Satisfaction, and Revenue
- NCT03175224 · 497 participants · Phase 2
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
- NCT05301816 · 497 participants · NA
PDN Post Market, Multicenter, Prospective, Global Clinical Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia